AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ABCD
Description: Participants receive test beverages in the randomised order ABCD
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence CADB
Description: Participants receive test beverages in the randomised order CADB
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DACB
Description: Participants receive test beverages in the randomised order DACB
Study NCT01755689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cervarix®
Description: Three doses administered intramuscularly (IM) in the deltoid of the left arm.
Study NCT01755689 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix®
Description: One dose administered intramuscularly (IM) in the deltoid of the left arm.
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence CBAD
Description: Participants receive test beverages in the randomised order CBAD
Study NCT05793710 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The principle of laughter plus Qigong
Description: The intervention program include muscle stretching, breathing exercises, and closing exercises. The laughing practice method begins with a warm-up consisting of laughing to stretch the body, yawning, and exerting the voice, and ends with expelling all the qi in order to return to natural movements and return to taking care of your body and mind (He et al., 2021).~The LQP program meets once a week for 90 minutes and runs for 12 weeks. The program content: the laughter skills were 50-60 minutes, the feedback was 30 minutes, and relaxation was 10 minutes.
Study NCT03134963 — intervention group
Intervention type: OTHER
Intervention: Heart rate monitoring
Description: Continuous heart rate monitoring
Study NCT01349010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Probucol
Description: 250mg (1 tablet) bid. p.o for 8 weeks
Study NCT01349010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 tablet bid. p.o for 8 weeks
Study NCT04055506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986165
Description: Dose 1
Study NCT04055506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg
Study NCT03325335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam premedication
Description: Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
Study NCT03134963 — intervention group
Intervention type: OTHER
Intervention: End tidal CO2 monitoring
Description: Continuous ETCO2 monitoring
Study NCT03325335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Remifentanil infusion
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
Study NCT03134963 — intervention group
Intervention type: OTHER
Intervention: Addenbrooke's cognitive examination
Description: Performance of a memory test
Study NCT04813679 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bed side Ultrasound Sonography
Description: Bed side Ultrasound in Neutropenic patients within 12 h from onset of any symptom such as fever and/or abdominal pain and/or diarreha
Study NCT03340493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
Study NCT03340493 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25mg/kg and 0.4mg/kg are being used
Study NCT01883583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced Ultrasound And Sonoelastography
Description: Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
Study NCT01848444 — intervention group
Intervention type: OTHER
Intervention: Breastmilk
Description: to measure levels of contaminants in human breastmilk samples
Study NCT01556919 — intervention group
Intervention type: PROCEDURE
Intervention: Standard of care endoscopy
Description: standard of care endoscopy
Study NCT03325335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil infusion
Description: Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
Study NCT03325335 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol infusion
Description: Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ABDC
Description: Participants receive test beverages in the randomised order ABDC
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DABC
Description: Participants receive test beverages in the randomised order DABC
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DCAB
Description: Participants receive test beverages in the randomised order DCAB
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence DBCA
Description: Participants receive test beverages in the randomised order BDCA
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ADCB
Description: Participants receive test beverages in the randomised order ADCB
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence BADC
Description: Participants receive test beverages in the randomised order BADC
Study NCT03325335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol infusion
Description: Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
Study NCT01541254 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Description: Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
Study NCT01022853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: intravenous each 21 days
Study NCT01022853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: oral continuously
Study NCT01463774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Canagliflozin tablet
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
Study NCT01463774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A: Metformin IR tablets
Description: Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
Study NCT01463774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B: Canagliflozin/metformin fixed dose combination tablets
Description: Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
Study NCT04762173 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Online self-help intervention
Description: Access to two online, self-guided programs available on the SilverCloud Health website.
Study NCT03873350 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consumption of kombucha
Description: The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of living kombucha daily for three weeks.
Study NCT03873350 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Consumption of heat-sterilized kombucha
Description: The intervention performed in the study implies letting healthy individuals consume one bottle (33 cl) of heat-sterilized kombucha daily for three weeks.
Study NCT04045223 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Maternal blood will be taken at arrival at the delivery unit and after delivery. Furthermore, placental blood will be taken after delivery.
Study NCT02634164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Supplement
Description: For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
Study NCT02634164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isoleucine Supplement
Description: For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
Study NCT02634164 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Leucine Supplement combined with Isoleucine Supplement
Description: For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
Study NCT02577432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
Study NCT02577432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
Study NCT02577432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Description: Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
Study NCT02577432 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hyperbaric bupivacaine
Description: Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
Study NCT03449238 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Pembrolizumab infusion will be given on Day 4 (+/-1) after SRS treatment at the standard dose of 200mg IV over 30 minutes and repeated every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02449577 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beverage sequence ACDB
Description: Participants receive test beverages in the randomised order ACDB
Study NCT04083144 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Deep Repetitive Transcranial Magnetic Stimulation (Active)
Description: Active deep rTMS (10 Hz) using the H-coil to target the bilateral insula
Study NCT04083144 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Deep Repetitive Transcranial Magnetic Stimulation (Sham)
Description: Sham deep rTMS using the H-coil. The sham coil is built into the same helmet as the active coil. It mimics the active coil with regards to acoustics and scalp sensations.
Study NCT04083144 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
Study NCT04083144 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Varenicline
Description: 12 week course treatment of varenicline (0.5 mg/1 mg) using the standard dosage schedule for smoking cessation (Day 1-3: 0.5 mg daily; day 4-7: 0.5 mg twice a day; day 8-end of treatment: 1 mg twice a day).
Study NCT02894983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Flexion-ulnar cast
Description: The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
Study NCT02894983 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Functional cast
Description: The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after 5 weeks.
Study NCT02948595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video feedback followed by structured verbal feedback
Description: Video feedback followed by structured verbal feedback
Study NCT02948595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured verbal feedback followed by video feedback
Description: Structured verbal feedback followed by video feedback
Study NCT01260415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab, Oxaliplatin, 5-FU
Description: * Panitumumab 6 mg / kg, given over 60 minutes~* Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR~* Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes~* 5FU 400 mg / m2, by bolus infusion~* 5FU 2400 mg / m2, given over 46 hours
Study NCT02504385 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Timocco
Description: Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
Study NCT02504385 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OT intervention
Description: Traditional Occupational Therapy intervention will be givven to the control group.
Study NCT01334112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib (AG-013736)
Description: 5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
Study NCT00828386 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Description: Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
Study NCT00828386 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy
Description: Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
Study NCT04194593 — intervention group
Intervention type: OTHER
Intervention: PCR (Polymerase Chain Reaction)
Description: Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).~A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm.
Study NCT01948934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Amniotic membrane in big wounds
Description: The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
Study NCT05024786 — intervention group
Intervention type: OTHER
Intervention: continuous quality improvements
Description: We implement the continuous quality improvement strategy in CQI group, and observe the effect of the strategy on the mortality of patients supported with ECMO .
Study NCT01399086 — intervention group
Intervention type: DRUG
Intervention: Fulvestrant
Description: 250mg on d1,15,29 or 250mg on d1 q28days
Study NCT04090749 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregiver-Support
Description: intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
Study NCT04090749 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caregiver-Support
Description: intervention incorporating 5 individualized, nurse-led, home-based sessions, with telephone check-ins and text reminders, according to participant preference. Caregiver-Support will help caregivers articulate statements of purpose in life, set goals to address fatigue and caregiver burden, provide instrumental support through a benefits check up and promote identification and increased connection with the caregiver's social network.
Study NCT02528305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity Interval Training
Description: 2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5\&6, 8 sprints in sessions 7\&8, 9 sprints in sessions 9\&10 and 10 sprints in sessions 11\&12.
Study NCT00672204 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic islets of Langerhans transplant
Description: Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
Study NCT00672204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raptiva
Description: Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
Study NCT00672204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
Study NCT00672204 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: 2.0 mg/kg on days -2, and -1 IV
Study NCT03325751 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Visual field testing
Description: Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
Study NCT02854475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Venous blood collection
Description: weekly within two weeks
Study NCT02854475 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy
Description: weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
Study NCT01503112 — intervention group
Intervention type: OTHER
Intervention: No intervention, observational study
Study NCT02652767 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GS010
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Participants will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®.
Study NCT02652767 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Intravitreal Injection
Description: Both eyes of each participant will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every participant.~Sham-treated Eyes: One eye of each participant will undergo sham injection. Sham intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle.